Agios Pharmaceuticals (AGIO) Stock Price, Quote & News

Company Profile

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatr...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 649 8600

Website: www.agios.com

Address:

88 Sidney Street, Cambridge, United States

Jadek6 Aug. 23 at 10:20 AM

$AGIO more than that , losers run the place

0 · Reply

LunarWatcher Aug. 23 at 4:58 AM

$AGIO Biopharma company with approved rare disease treatment but facing commercialization challenges

0 · Reply

Tumble51 Aug. 22 at 5:37 PM

$AGIO 200,000 shares shorted at this level !! TODAY !!! No buyers here , just buffoons

0 · Reply

Tumble51 Aug. 22 at 4:59 PM

$AGIO true !

0 · Reply

wrengler4 Aug. 22 at 3:40 PM

$AGIO no power houses here placing bets on the 3 stooges !! Hahaha..they could fcuk up Kool Aide !!

0 · Reply

wrengler4 Aug. 22 at 1:58 PM

$AGIO All green moments are followed by reality of : RED

0 · Reply

wrengler4 Aug. 22 at 1:56 PM

$AGIO RED !!! The mascot color for 7 years as Fouse walked on the property !! PSU are @125 ..she won’t be able to receive them , haha

0 · Reply

wrengler4 Aug. 22 at 12:26 PM

$AGIO just saying Does anyone here know if the senior misfits know that their ACTION DATE FROM THE FDA , will be closed Hahahahahaha ..they profess it will come the 7th of Sept ! Hell my calendar says it is Sunday Again , like always , even under Schenkien, they continue to LIE to the public here. It is a disease, they have no cure for !!!

0 · Reply

Jadek6 Aug. 22 at 11:23 AM

$AGIO hell ..you don’t read the hints laced thru this medium about Schenkien, Fouse and Goff The three stooges …shame is on you ! Even an FDA date of September 7 is their stupidity as well FDA announcements come on Thursdays !!! After the market closes .. Check ALNY’s very first approval ..Sept 7, 2017 , a month early , why ???? John Maraganore was a professional, brilliant leader and the fDA knew it , these clowns are hacks

0 · Reply

lnoa Aug. 22 at 10:06 AM

$AGIO just in 30s !! So frustrating! Hiding for years!! Will out as good to take loss !! Can’t wait anymore

0 · Reply

Agios' PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in Saudi Arabia

Jul 31, 2025, 5:02 PM EDT - 24 days ago

Agios Pharmaceuticals, Inc. (AGIO) Q2 2025 Earnings Call Transcript

Jul 31, 2025, 6:30 AM EDT - 24 days ago

Agios Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 14, 2025, 7:00 AM EDT - 5 weeks ago

Agios to Host Webcast Conference Call of Second Quarter Financial Results on July 31, 2025 at 8:00am ET

Jul 8, 2025, 7:00 AM EDT - 6 weeks ago

Agios Appoints Dr. Jay Backstrom to Board of Directors

Jun 9, 2025, 8:40 AM EDT - 2 months ago

Avanzanite Announces Pan-European Partnership with Agios to Launch PYRUKYND® in Rare Blood Disorders

May 28, 2025, 7:00 AM EDT - 3 months ago

Agios to Present at Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025

May 14, 2025, 10:00 AM EDT - 3 months ago

Agios to Highlight Pyruvate Kinase Activation Portfolio with New Data in Rare Blood Disorders at 30th EHA Congress

May 9, 2025, 7:00 AM EDT - 3 months ago

Agios to Present at the 2025 RBC Capital Markets Global Healthcare Conference on May 21, 2025

May 2, 2025, 7:00 AM EDT - 4 months ago

Agios to Present at the BofA Securities 2025 Health Care Conference on May 14, 2025

May 1, 2025, 12:06 PM EDT - 4 months ago

Agios Pharmaceuticals, Inc. (AGIO) Q1 2025 Earnings Call Transcript

May 1, 2025, 6:30 AM EDT - 4 months ago

Agios Reports First Quarter 2025 Financial Results and Recent Business Highlights

Apr 17, 2025, 7:00 AM EDT - 4 months ago

Agios to Webcast Conference Call of First Quarter Financial Results on May 1, 2025

Mar 5, 2025, 5:52 PM EST - 6 months ago

Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Corporate Development & Strategy Officer

Mar 4, 2025, 7:00 AM EST - 6 months ago

Agios to Present at Upcoming Investor Conferences

Feb 20, 2025, 7:00 AM EST - 6 months ago

Agios to Present at the TD Cowen 45th Annual Healthcare Conference on March 3, 2025

Feb 13, 2025, 1:32 PM EST - 6 months ago

Agios Pharmaceuticals, Inc. (AGIO) Q4 2024 Earnings Call Transcript

Feb 13, 2025, 6:31 AM EST - 6 months ago

Agios Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Feb 13, 2025, 6:30 AM EST - 6 months ago

Agios' Phase 3 ACTIVATE-Kids Study of Mitapivat in Children with Pyruvate Kinase (PK) Deficiency Not Regularly Transfused Met Primary Endpoint

Feb 6, 2025, 7:00 AM EST - 7 months ago

Agios to Webcast Conference Call of Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025

Jan 8, 2025, 8:00 AM EST - 8 months ago

Cardurion Pharmaceuticals Appoints Charlotte Newman as Chief Business Officer

BIIB

Jan 3, 2025, 7:00 AM EST - 8 months ago

Agios to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025

Dec 18, 2024, 7:00 AM EST - 8 months ago

European Commission Adopts Positive Decision for Orphan Medicinal Product Designation of Agios' Mitapivat in Sickle Cell Disease

Dec 8, 2024, 12:40 PM EST - 9 months ago

Agios Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on Mitapivat

Nov 5, 2024, 9:05 AM EST - 10 months ago

Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition

Oct 31, 2024, 2:16 PM EDT - 10 months ago

Agios Pharmaceuticals, Inc. (AGIO) Q3 2024 Earnings Call Transcript

Oct 31, 2024, 6:30 AM EDT - 10 months ago

Agios Reports Business Highlights and Third Quarter 2024 Financial Results

Oct 17, 2024, 7:00 AM EDT - 11 months ago

Agios to Webcast Conference Call of Third Quarter 2024 Financial Results on October 31, 2024

Sep 11, 2024, 7:00 AM EDT - 1 year ago

Agios Announces FDA Orphan Drug Designation Granted to Tebapivat (AG-946) for Treatment of Myelodysplastic Syndromes (MDS)

Sep 5, 2024, 7:00 AM EDT - 1 year ago

Agios to Present at the 2024 Cantor Global Healthcare Conference on September 18, 2024

Aug 27, 2024, 10:18 AM EDT - 1 year ago

Agios' Mitapivat: A Potential Blockbuster In Thalassemia Treatment

Aug 6, 2024, 5:50 PM EDT - 1 year ago

Agios to Receive $1.1 Billion in Milestone Payments Following FDA Approval of Vorasidenib

Aug 1, 2024, 1:42 PM EDT - 1 year ago

Agios Pharmaceuticals' Rare Blood Disorder Drug Misses Primary Goal In Pediatric Study, Stock Slides

Aug 1, 2024, 12:11 PM EDT - 1 year ago

Agios Pharmaceuticals, Inc. (AGIO) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 6:31 AM EDT - 1 year ago

Agios Reports Business Highlights and Second Quarter 2024 Financial Results

Aug 1, 2024, 6:30 AM EDT - 1 year ago

Agios Announces Results from Phase 3 ACTIVATE-KidsT Study of Mitapivat in Children with PK Deficiency Who Are Regularly Transfused

Jul 18, 2024, 7:00 AM EDT - 1 year ago

Agios to Webcast Conference Call of Second Quarter 2024 Financial Results on August 1, 2024

Jun 12, 2024, 7:41 AM EDT - 1 year ago

Agios Pharmaceuticals: Potential Acquisition Target, Upcoming FDA Approvals, Promising Pipeline

Jun 3, 2024, 6:42 AM EDT - 1 year ago

Agios Pharmaceuticals' blood disorder drug succeeds in late-stage study

Jun 3, 2024, 6:30 AM EDT - 1 year ago

Agios Announces Phase 3 ENERGIZE-T Study of Mitapivat Met Primary Endpoint and All Key Secondary Endpoints in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia

May 30, 2024, 4:05 PM EDT - 1 year ago

Agios to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024

May 14, 2024, 10:00 AM EDT - 1 year ago

Agios Pharmaceuticals to Present Clinical and Translational Data in Rare Blood Disorders at European Hematology Association 2024 Hybrid Congress

May 3, 2024, 7:00 AM EDT - 1 year ago

Agios to Present at the RBC Capital Markets Global Healthcare Conference on May 14, 2024

May 2, 2024, 4:32 PM EDT - 1 year ago

Agios Pharmaceuticals, Inc. (AGIO) Q1 2024 Earnings Call Transcript

May 2, 2024, 7:00 AM EDT - 1 year ago

Agios Reports Business Highlights and First Quarter 2024 Financial Results

Apr 18, 2024, 7:00 AM EDT - 1 year ago

Agios to Webcast Conference Call of First Quarter 2024 Financial Results on May 2, 2024

Mar 5, 2024, 7:00 AM EST - 1 year ago

Agios to Present at the Leerink Partners Global Biopharma Conference on March 12, 2024

Feb 22, 2024, 7:00 AM EST - 1 year ago

Agios to Present at the TD Cowen 44th Annual Health Care Conference on March 4, 2024

Feb 15, 2024, 2:08 PM EST - 1 year ago

Agios Pharmaceuticals (AGIO) Q4 2023 Earnings Call Transcript

Feb 15, 2024, 7:00 AM EST - 1 year ago

Agios Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

Jadek6 Aug. 23 at 10:20 AM

$AGIO more than that , losers run the place

0 · Reply

LunarWatcher Aug. 23 at 4:58 AM

$AGIO Biopharma company with approved rare disease treatment but facing commercialization challenges

0 · Reply

Tumble51 Aug. 22 at 5:37 PM

$AGIO 200,000 shares shorted at this level !! TODAY !!! No buyers here , just buffoons

0 · Reply

Tumble51 Aug. 22 at 4:59 PM

$AGIO true !

0 · Reply

wrengler4 Aug. 22 at 3:40 PM

$AGIO no power houses here placing bets on the 3 stooges !! Hahaha..they could fcuk up Kool Aide !!

0 · Reply

wrengler4 Aug. 22 at 1:58 PM

$AGIO All green moments are followed by reality of : RED

0 · Reply

wrengler4 Aug. 22 at 1:56 PM

$AGIO RED !!! The mascot color for 7 years as Fouse walked on the property !! PSU are @125 ..she won’t be able to receive them , haha

0 · Reply

wrengler4 Aug. 22 at 12:26 PM

0 · Reply

Jadek6 Aug. 22 at 11:23 AM

0 · Reply

lnoa Aug. 22 at 10:06 AM

$AGIO just in 30s !! So frustrating! Hiding for years!! Will out as good to take loss !! Can’t wait anymore

0 · Reply

Dkll303 Aug. 21 at 6:47 PM

$ALNY got the wrong ticker !! John Maraganore put his stamp here You are thinking of David Schenkien and his failure and failures , Fouse and GOFF !!! At $AGIO

0 · Reply

Dkll303 Aug. 21 at 6:45 PM

$AGIO And , the algos run it a bit while dotting it with short bets They win ..hahaha $37 for centuries

0 · Reply

wrengler4 Aug. 21 at 11:35 AM

$AGIO Add RED already !!!

0 · Reply

wrengler4 Aug. 21 at 11:16 AM

$AGIO $QURE check out the history of Matt Kapusta at QURE and his selling of options in 2021, 2022 and 2023 in the 30’s , much like the antics of goof ball GOFF, here … No investor makes money , due to there inabilities to create value , but the bozos sell each chance they get !! GOFF DOESNT GIVE A FCUK ..it is the MATT KAPUSTA theory : MILK THE SOB as long as you can before they oust you for : poor performance for inside fund shareholders !!! GOFF has brought no value in 3 years this month ! FOUSE NEVER DID !!! she created a NEW HISTORIC LOW $16.95 from $62.10 !!!! ( but she was always a loser from Bunge and discarded from Celgene , but was David Schenkien’s girl,Friday ) The game is the same with these two losers , Kapusta and Goff !!! David Meeker , $RYTM, are you reading this ??? Your RYTM was $3 in 2023, today $98 !!! Guess one knows , WHO is with creating value and WHOM ARE NOT !!!!

0 · Reply

Dkll303 Aug. 19 at 1:04 PM

$AGIO 2573 to 2590 ….a stock no one knows about due to the lack of GOFF OR FOUSE to communicate Says , only the shorts are watching ….NO BUYERS STILL Hahahaha 7 years of the FOUSE EFFECT 3 years of The GOOF GOFF effect Twin losers

0 · Reply

Tumble51 Aug. 19 at 11:56 AM

$AGIO shorts have increased their watching here, lol !! GOFF doesn’t know he has a mole in the company , lol Fouse, she was born clueless and sucked down on many a public company

0 · Reply

Jadek6 Aug. 18 at 12:14 PM

$AGIO appears from the commentary, Senior executives will fcuk it up anyway , history here of their screw ups is well noted ! @TomMac64

0 · Reply

TomMac64 Aug. 18 at 8:53 AM

$AGIO $BEAM We are not years to approval go back and read the press release !

0 · Reply

Doozio Aug. 17 at 10:37 PM

$AGIO out of 🐑⏰♾️ all them bums been SPOT on 8/4 MNDY 🐑 lows and new Baker Bros during 🐒🍌🧠⏰♾️

0 · Reply

justiceforb_85 Aug. 17 at 4:09 AM

$AGIO think this will see positive action with expanded indication for mitapivat in thalassemia.

0 · Reply

Tumble51 Aug. 16 at 2:16 AM

$AGIO Let us see how , Fouse and Goff , fcuk up the lead they have over BEAM ,another Cambridge, Mass biotech They fcuk everything else up. $BEAM is in phase 1/2 …years to an approval , but Goff , still could fcuk up,his lead ..He is that bad !!!

1 · Reply

Dkll303 Aug. 15 at 6:16 PM

$AGIO the daily BLEED here But when insiders sell at this price Smart money says..like Hunter Biden FCUK THAT !!!! We see the same here ..Fouse was Schenkien's wing man with little science knowledge Goff followed as a pathetic choice , but he was laid off and no moving expenses , hahahah

0 · Reply

Market Cap	2.25B
Revenue (ttm)	36.50M
Net Income (ttm)	673.73M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	1,845.84%
Debt to Equity Ratio	0.00

Volume	722,500
Avg Vol	777,470
Day's Range	N/A - N/A
Shares Out	58.10M
Stochastic %K	81%
Beta	0.80
Analysts	Strong Sell
Price Target	$50.00